PMZ 1620

Drug Profile

PMZ 1620

Alternative Names: IRL-1620; PMZ-1620; SPI-1620

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Illinois at Chicago
  • Developer Pharmazz; Spectrum Pharmaceuticals
  • Class Antineoplastics; Peptides; Vasodilators
  • Mechanism of Action Angiogenesis inducing agents; Diagnostic imaging enhancers; Endothelin B receptor agonists; Neurogenesis stimulants; Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Stroke
  • Clinical Phase Unknown Solid tumours
  • Preclinical Cerebrovascular disorders; Neurodegenerative disorders
  • Discontinued Biliary cancer; Non-small cell lung cancer

Most Recent Events

  • 13 Feb 2017 Discontinued - Phase-I for Solid tumours (Adjunctive treatment, Second-line therapy or greater) in USA (IV) prior to February 2017
  • 13 Feb 2017 Discontinued - Phase-II for Biliary cancer (Adjunctive treatment, Late-stage disease, Second-line therapy or greater) in USA (IV) prior to February 2017
  • 13 Feb 2017 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) prior to February 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top